PharmaFocus Today – Page 4 – media

The world’s largest superconducting magnet machinery company is aiming for an IPO

Recently, according to the official website of the Shanghai Stock Exchange, the IPO application of Ningbo Jianxin Superconducting Technology Co., Ltd. (hereinafter referred to as Jianxin Superconducting) on the Science and Technology Innovation Board has been accepted. It is worth mentioning that the company has become the third company to be accepted on the Science and Technology Innovation Board in 2025. According to the prospectus, Jianxin Superconducting is mainly engaged in the research and development, production and sales of core components of medical magnetic resonance imaging (MRI) equipment. The company was founded in 2013. After years of development in the MRI industry, its main products are now widely deployed in the MRI field, including superconducting magnets, permanent magnets and gradient coils. In addition, Jianxin Superconducting has mastered a number of core technologies in the MRI field and is committed to implementing the technology. It is worth mentioning that Jianxin Superconducting ...
- Source: drugdu
- 37
- May 19, 2025
Wearable defibrillator patch is approved

Recently, Element Science announced that its wearable defibrillator patch has been approved by the U.S. Food and Drug Administration (FDA) after being approved by British and European regulators early last year. This non-invasive device provides an innovative solution for patients with a temporarily increased risk of cardiac arrest. It is reported that the device is suitable for patients recovering from heart attacks and other patients with serious cardiovascular diseases. The Jewel Patch-WCD wearable cardioverter defibrillator system adopts a lightweight and waterproof design, which supports continuous wear during sleep and showering. The system includes a reusable defibrillator device, a battery pack, and a disposable electrode patch that is replaced once a week. Uday Kumar, President and CEO of Element Science, said that the Jewel patch-type external defibrillator has realized the vision of seamlessly integrating life-saving equipment into patients’ daily lives. This FDA approval not only means the achievement of a regulatory ...
- Source: drugdu
- 36
- May 19, 2025
Discovery of mutated immune cell clones could point to improved treatment for refractory celiac disease

Scientists have identified mutated immune cell clones that could point to improved treatment for refractory celiac disease. Researchers at the Garvan Institute of Medical Research and UNSW Sydney have discovered why some people with celiac disease continue to suffer debilitating symptoms despite strictly avoiding gluten. The study, published in Science Translational Medicine, used cutting-edge single-cell sequencing techniques to reveal that certain immune cells in the gut of these patients carry genetic mutations. The team’s findings suggest these abnormal immune cells are driving ongoing intestinal inflammation that causes symptoms like diarrhoea, pain and malnutrition – pointing to a new way to diagnose and potentially treat the most severe form of celiac disease. Rogue immune cells emerge as hidden culprits celiac disease is a chronic autoimmune condition where the body mistakenly attacks the small intestine in response to gluten, a protein found in wheat, barley and rye. While most people with ...
- Source: drugdu
- 37
- May 19, 2025
HHS, FDA Begin ‘Operation Stork Speed’ to Improve Quality of Infant Formula

The U.S. Department of Health and Human Services and U.S. Food and Drug Administration have begun to comprehensively review the nutritional value of infant formula, a program the agencies have dubbed Operation Stork Speed. Operation Stork Speed aims to review the nutrient content of infant formula, increase testing for heavy metals and contaminants, encourage companies to develop new formulas, and clarify ways to better inform consumers about formula ingredients. Individual nutrient requirements for infant formula are already reviewed at regular intervals; however, this will be the first comprehensive review since 1998. The FDA has initiated Operation Stork Speed with a Request for Information (RFI) to gather public input. This input will be used to evaluate whether current nutrient requirements need to be updated based on the most recent scientific findings, including international data. The agency is also interested in receiving input regarding potential adjustments to the current minimum or maximum ...
- Source: drugdu
- 34
- May 19, 2025
Pharmaron grants technology license to shareholder Juno; Shiyao Group Enters into Exclusive License Agreement | Pharmaceutical Early Ginseng

NO.1 Shiyao Group enters into exclusive license agreement for irinotecan liposome injection On May 15th, Shiyao Group announced that it has entered into an exclusive license agreement with Cipla USA, Inc. for the commercialization of irinotecan liposome injection in the United States. According to the terms, the group will receive a down payment of $15 million and is also entitled to receive up to $25 million in potential initial commercial sales and regulatory milestone payments, as well as up to $1.025 billion in potential additional commercial sales milestone payments, and a double-digit gradient sales commission calculated based on the annual net sales of the product in the region. Comment: This event is an important breakthrough in the company’s internationalization strategy. The potential transaction volume of over 1 billion US dollars demonstrates the huge commercial potential of Irinotecan Liposome Injection in the US market, and also reflects the strong strength of ...
- Source: drugdu
- 36
- May 19, 2025
In the first quarter, BeiGene reduced losses and accelerated the commercialization of innovative drugs

BeiGene Limited (referred to as “BeiGene”, 688235. SH) recently released its Q1 2025 financial report, which showed that the company’s operating revenue reached 8.048 billion yuan, an increase of 50.2% compared to the same period last year’s 5.359 billion yuan. In terms of net profit, the company still faces certain pressure to incur losses, but the losses have significantly narrowed. The net profit attributable to the parent company was a loss of 94.503 million yuan, a significant reduction from the loss of 1.908 billion yuan in the same period last year. From the perspective of cost structure, BeiGene continues to increase its research and development investment. Data shows that BeiGene’s research and development expenses in 2024 amounted to 14.14 billion yuan, an increase of 10.35% compared to the same period last year. Research and development investment is used for preclinical studies, clinical trials, collaborative research and development of the company’s ...
- Source: drugdu
- 33
- May 19, 2025
How Can Pharmaceutical Exporters Secure Their First Overseas Distributor?— A Practical Guide from Sourcing to Evaluation and Negotiation

In the field of pharmaceutical foreign trade, finding a suitable overseas distributor is often the most direct and effective way to penetrate a new national or regional market. However, for companies that are new to export, questions like “How do I find a distributor?”, “How can I assess if they are trustworthy?”, and “How do I maintain control during negotiations?” can be daunting. This article offers a hands-on guide to help pharmaceutical exporters navigate the entire process—from zero to one—and take their first step in global channel development. 1. Define the Type of Distributor You Need Different products and markets require different types of distributors. Before you start the search, align your internal team on the following key points: Do you need an exclusive distributor, or are you open to multi-distributor models? Do you require specific channel types (hospitals, retail pharmacies, e-commerce, wholesalers)? Will you need the ...
- Source: drugdu
- 46
- May 16, 2025
Trump signs executive order to lower prescription drug prices, expected to have limited short-term impact

According to a research report by CITIC Securities, on May 12th, Trump signed an executive order titled “Providing Most Favored Nation Prices for Prescription Drugs to American Patients,” aimed at lowering prescription drug prices in the US market. Trump proposed “most favored nation” prices in the executive order, requiring pharmaceutical companies to sell their drugs in the United States at prices equal to the lowest prices in comparable developed countries. At the same time, Trump also proposed to increase the transparency of drug prices in the United States and reduce the profit margin of middlemen represented by PBM. CITIC Securities believes that the implementation of this administrative order is difficult and the short-term impact on the industry is expected to be limited. The full text is as follows Drugs and Innovation | Trump signs executive order to lower prescription drug prices, expected to have limited short-term impact On May 12, ...
- Source: drugdu
- 50
- May 16, 2025
Huasen Pharmaceutical plans to hold a controlling stake in Aorui Pharmaceutical to promote the development of innovative drugs in the fields of oncology and immunotherapy

On the evening of May 14th, Huasen Pharmaceutical announced that in order to integrate and supplement its innovative drug research and development pipeline, further strengthen its own innovative drug research and development capabilities, and accelerate transformation and upgrading, the company and its wholly-owned subsidiary – Chongqing Huasen Yingnuo Biotechnology Co., Ltd. (referred to as “Huasen Yingnuo”) and existing shareholders Yang Shengyong, Huang Qi, etc. of Chengdu Aorui Pharmaceutical Co., Ltd. (referred to as “Aorui Pharmaceutical”) have signed a “Equity Change Agreement”. Huasen Yingnuo will acquire 37.3619% equity of Aorui Pharmaceutical for free as compensation for the repurchase obligations of relevant shareholders in the historical transaction documents of the company and Huasen Yingnuo. After the completion of this equity transfer, in addition to the 28.6381% equity previously held by the company in Aorui Pharmaceutical, the company and its subsidiaries will hold a total of 66% equity in Aorui Pharmaceutical, which will ...
- Source: drugdu
- 47
- May 16, 2025
New Drug Combos Could Cut Heart Failure Mortality by 60%

Optimized treatment can reduce the mortality risk for chronic heart failure (HF) by as much as 60%. The role of appropriate drug combinations and rapid diagnosis was discussed at the 91st Annual German Society of Cardiovascular Medicine Annual Conference. “It is important to start drug treatment for HF immediately after diagnosis, in parallel with investigating the underlying causes, as the benefits of treatment appear very quickly,” said Birgit Assmus, MD, cardiologist and head of the Heart Failure Department of the University Hospital of Giessen and Marburg, Marburg, Germany. Recommended Treatment For HF with reduced ejection fraction (HFrEF) and a left ventricular ejection fraction (LVEF) ≤ 40%, as well as for HF with moderately reduced ejection fraction (LVEF between 41% and 49%), the 2021 European Society of Cardiology (ESC) guidelines recommend a quadruple combination of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor/neprilysin inhibitors (ARNI), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and sodium-glucose ...
- Source: drugdu
- 51
- May 16, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.